WO29519 (MIRROS) (R/R)

WO29519 (MIRROS) (R/R)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)


Study treatments


Inclusion criteria


Exclusion criteria


Participating sites

Link